Skip to main content

Peer Review reports

From: Integrating network pharmacology, bioinformatics, and experimental validation to unveil the molecular targets and mechanisms of galangin for treating hepatocellular carcinoma

Original Submission
18 Dec 2023 Submitted Original manuscript
29 Dec 2023 Reviewed Reviewer Report - Talha Bin Emran
2 Jan 2024 Reviewed Reviewer Report
30 Jan 2024 Author responded Author comments - Junqing Zhang
Resubmission - Version 2
30 Jan 2024 Submitted Manuscript version 2
15 Feb 2024 Author responded Author comments - Junqing Zhang
Resubmission - Version 3
15 Feb 2024 Submitted Manuscript version 3
23 Feb 2024 Author responded Author comments - Junqing Zhang
Resubmission - Version 4
23 Feb 2024 Submitted Manuscript version 4
26 Feb 2024 Author responded Author comments - Junqing Zhang
Resubmission - Version 5
26 Feb 2024 Submitted Manuscript version 5
28 Feb 2024 Reviewed Reviewer Report - Talha Bin Emran
13 Mar 2024 Reviewed Reviewer Report
30 Mar 2024 Author responded Author comments - Junqing Zhang
Resubmission - Version 6
30 Mar 2024 Submitted Manuscript version 6
16 Apr 2024 Reviewed Reviewer Report - Talha Bin Emran
23 Apr 2024 Reviewed Reviewer Report
7 May 2024 Author responded Author comments - Junqing Zhang
Resubmission - Version 7
7 May 2024 Submitted Manuscript version 7
17 May 2024 Reviewed Reviewer Report - Talha Bin Emran
Resubmission - Version 8
Submitted Manuscript version 8
Publishing
23 May 2024 Editorially accepted
30 May 2024 Article published 10.1186/s12906-024-04518-x

You can find further information about peer review here.

Back to article page